il-2-secreting cd40l-expressing autologous b-cll cells
Vaccineexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2002 (NCT00058786)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD40-CD40LImmunity, passive
CD40-CD40L immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- il-2-secreting cd40l-expressing autologous b-cll cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00058786 | Phase 1 | Dec 1, 2002 | Baylor University, Methodist Cancer Center, Houston, Texas |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2002 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2002 |
2 organizations
Page 1 / 1